Navigation Links
Some breast cancer spread may be triggered by a protein, study shows
Date:1/17/2012

Cancers rarely are deadly unless they evolve the ability to grow beyond the tissues in which they first arise. Normally, cells -- even early-stage tumor cells -- are tethered to scaffolding that helps to restrain any destructive tendencies. But scientists from the University of Helsinki, Finland, and from UCSF have identified a cleaver-wielding protein that frees some tumor cells, allowing them to further misbehave.

The protein, they discovered, often blankets the surface of breast tumor cells and can help untether the cells from the matrix of their native tissue. Once released, they may continue to expand their numbers into other tissues where their normal counterparts do not tread.

The protein, called hepsin, is a protease, a class of enzymes that cleaves, or cuts, other proteins. Proteases have been targeted successfully by drugs, and hepsin presents a new possible drug target, the researchers said.

"If we could delay or prevent a tumor from switching from one that grows in place to one that invades, then that would be a major milestone in cancer treatment," said study co-author Zena Werb, PhD, a professor of anatomy at UCSF. Werb has for decades studied the ways in which the behavior of tumor cells is influenced by their surroundings, with a focus on breast tumors.

Working with mouse models of breast development and breast cancer in Werb's UCSF laboratory during a visiting professorship, University of Helsinki scientist Juha Klefstrm, PhD -- along with Johanna Partanen, a University of Helsinki graduate student -- designed and led experiments that resulted in the discovery of the hepsin protein's role.

Their findings are published in the January 16, 2012 edition of the Proceedings of the American Academy of Sciences (PNAS).

The scientists studied mammary glands in mice and tissue fragments called organoids isolated from these glands.

They found that inactivation of a tumor suppr
'/>"/>

Contact: Jeffrey Norris
jeffrey.norris@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Researchers identify possible receptor for key breast cancer regulator
2. ISG15: A novel therapeutic target to slow breast cancer cell motility
3. Cell-CT: A new dimension in breast cancer research
4. Breastfeeding promotes healthy growth
5. Breastfeeding saved babies in 19th century Montreal
6. MRI may be noninvasive method to measure breast cancer prognosis
7. New Achilles heel in breast cancer: Tumor cell mitochondria
8. USC researchers discover key aspect of process that activates breast cancer genes
9. HDAC inhibitor may overcome resistance to common breast cancer drug
10. Benefit of novel drug in breast cancer seen in blood within weeks
11. Signaling pathway linked to inflammatory breast cancer may drive disease metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Some breast cancer spread may be triggered by a protein, study shows
(Date:5/25/2015)... 25, 2015  Australia,s market for wearable technologies is ... saw the advent of several trials and prototypes. The ... is expected to ignite interest in wearables as well ... Australia . This in turn will spur greater ... new partnerships amongst vendors and distributors. ...
(Date:5/21/2015)... , May 21, 2015 ... "Thermal Imaging Market by Solutions (Hardware, Software, Services), by ... Automotive & others), by End-Users (Military & Defense ... by MarketsandMarkets, Thermal Imaging Market is expected to ... Million by 2020, at a Compound Annual Growth ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Jrgen Kjems and Morten Trillingsgaard Ven, Department of Molecular ... contribute to an article on microRNA-128 just published in ... was possible to control the amount of microRNA-128 in ... "If microRNA-128 is kept down in these neurons in ...
... Ariz. A group of researchers from Arizona State University ... in the study of human proteins that could open up ... work is being reported in this week,s Science ... G-protein-coupled receptors," the team reports that they have been successful ...
... New York have reported the successful transformation of vegetable ... a structuring agent. The findings portend the development of ... acids, which have been linked to coronary artery disease, ... College Professor of Chemistry George John, tested two sugar ...
Cached Biology News:New research provides insight into epilepsy 2ASU researchers develop new device to help image key proteins at room temperature 2ASU researchers develop new device to help image key proteins at room temperature 3CCNY chemists use sugar-based gelators to solidify vegetable oils 2
(Date:6/1/2015)... BATON ROUGE, La. , June 1, 2015 /PRNewswire/ ... a Phase II trial of lead candidate EP-100 in ... targeted membrane-disrupting peptide designed to seek and destroy cancer ... their surfaces. LHRH receptors are over-expressed in a wide ... randomized, multi-center Phase II trial of EP-100 ...
(Date:6/1/2015)... -- Shire plc (LSE: SHP, NASDAQ: ... the Jefferies 2015 Global Healthcare Conference in ... 2015. Jeff Poulton , Chief Financial Officer will ... a.m. ET (3:00 p.m. BST). A live ... Webcasts section of Shire,s Investor website at http://investors.shire.com/presentations-and-webcasts/year-2015.aspx ...
(Date:6/1/2015)... 1, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced positive, new, ... trial of AST-VAC1 in patients with intermediate and ... the Company,s autologous (using cells sourced from the ... the most common form of acute leukemia in ...
(Date:5/31/2015)... , May 31, 2015 Halozyme ... company developing novel oncology and drug-delivery therapies, today ... clinical study of its investigational new drug PEGPH20 ... pancreatic cancer. The encouraging interim data ... Clinical Oncology annual meeting in an oral presentation ...
Breaking Biology Technology:Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 2Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 3Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 4Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 5Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 6Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML) 7Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5
... for Talent is opening up. Tens of millions of people ... join, or are already in, the workforce - bringing expectations, ... Those organizations that can inspire the passion and harness the ... their competitors. Here's why. , ,Until recently, workers of ...
... note: Janet Dillione is president of the health services ... largest medical technology companies. She has something in common with Donna ... - both recently were named among the Top 25 women in ... are some excerpts from a recent WTN interview with Dillione. ...
... Court has issued several rulings that have eroded the strength ... v. AT&T , the Supreme Court delivered another blow by ... law governs domestically but does not rule the world. , , ... Court addressed Section 271(f) of the patent code, which prohibits a ...
Cached Biology Technology:Media-savvy workers: New front in the War for Talent 2Media-savvy workers: New front in the War for Talent 3Media-savvy workers: New front in the War for Talent 4Media-savvy workers: New front in the War for Talent 5Siemens health services president calls IT benefits unassailable 2Siemens health services president calls IT benefits unassailable 3Siemens health services president calls IT benefits unassailable 4Siemens health services president calls IT benefits unassailable 5Supreme Court limits foreign reach of U.S. patents 2Supreme Court limits foreign reach of U.S. patents 3Supreme Court limits foreign reach of U.S. patents 4
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
interferon-related developmental regulator 2...
Biology Products: